Topical high-potency corticosteroid

PreclinicalSmall molecule

FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Topical high-potency corticosteroid is one of 2 small molecule programs targeting Vulvar Lichen Sclerosus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vulvar Lichen SclerosusRecruiting

Vulvar Lichen SclerosusPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Vulvar Lichen Sclerosus

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 2

1 2

Topical high-potency corticosteroid

FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

N/ARecruiting

Vulvar Lichen Sclerosus

NCT07363733

Clinical

Trials by Indication[1]

Vulvar Lichen Sclerosus1 trial

Dynamic Quadripolar Radiofrequency VS Topical Corticosteroids in Women With Vulvar Lichen Sclerosus

Recruiting·FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare·N/A·NCT07363733·68 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Topical high-potency corticosteroid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical high-potency corticosteroid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical high-potency corticosteroid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFederal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare

Topical high-potency corticosteroid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Vulvar Lichen Sclerosus1 trial

References

Drug Info

Quick Facts

Related News